Matched sibling donors (MSD) and matched unrelated donors (MUD) continue to yield the best 2-year survival outcomes following allogeneic hematopoietic cell transplantation (HCT), while mismatched ...

Benjamin Izar, MD, PhD, discusses unmet needs in melanoma including drug resistance and brain and liver metastases. During a visit to Columbia University’s Herbert Irving Comprehensive Cancer Center, ...

This week in oncology, the FDA expanded the treatment landscape for platinum-resistant ovarian cancer with a new approval, and significant clinical data emerged regarding novel in ...

Final analysis from the phase 2 OVATION 2 trial (NCT03393884) has demonstrated a continued and growing overall survival (OS) ...

Transdermal estradiol offers fewer hot flashes and lower fracture rates, but higher rates of gynecomastia, as it meets the ...

Frontline gastric/GE junction cancer care now pairs chemo with checkpoint inhibitors for PD-L1 CPS≥1, improving survival and ...

Menin inhibitors reshape AML care, boosting targeted options for KMT2A- and NPM1-mutant disease, with promising frontline ...

Phase 2b data show RAD101 amino acid PET hits 90% concordance, helping distinguish brain metastasis recurrence from ...

When contextualized with the developments across all genitourinary [GU] malignancies, especially renal cell carcinoma and ...

Learn how age, TP53 risk, and lifestyle shape choosing fixed-duration vs continuous CLL therapy, with shared decision tips from Dr Lamanna. While results from the CLL17 trial (NCT04608318) suggest ...

With thoracic oncology in the middle of a combinatorial revolution—EGFR-targeted doublets and triplets, a maturing ...

Phase 2 TBCRC049 trial results show tucatinib triplet therapy improves survival in HER2+ breast cancer patients with ...